1Saacli Z, Inaba K,Barmparas G, et al. Extreme thrombocy- tosis in trauma patients:are antiplatelet agents the answer [J]. Am Surg,2009,75(10) :1020- 1024.
2Tefferi A,Thiele J,Orazi A,et al. Proposals and rationale for revision of the world health organization diagnostic criteria for polycythemia vera essential thrombocythemia and primary myelofibrosis recommendations from an ad hoe international expert panel [J]. Blood, 2007,110 (4) : 1092-1097.
3Wadleigh M, Tefferi A. Classification and diagnosis of myelopmliferative neoplasms according to the 2008 World Health Organization criteria[J]. Int J Hematol, 2010,91 (2):174-179.
2[1]JOHANSSON P.Epidemiology of the myeloproliferative disorders polycytothemia vera and essential thrombocythemia[J].Sem Thromb Haemost,2006,32(3):171-173.
3[2]BAXTER EJ,SCOTT LM,CAMPELL PJ,et al.Aquired mutation of the tyrosine kinase JAK2 in human myeloproliferative sid]sorders[J].Lancet,2005,365:1054-1061.
4[3]JAMES C,UGO V,Le COUEDIC JP,et al.A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera[J].Nature,2005,434:1144-1148.
5[4]LIPPERT E,BOISSINOT M,KRALOVICS R,et al.The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera[J].Blood,2006,108:1865-1867.
6[5]RANDI ML,PUTTI MC,SCAPIN M,et al.Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative[J].Blood,2006,108:3600-3602.
7[6]VASSILIOU GS,CAMPBELL PJ,LI J,An acquired translocation in JAK2 Val617Phe-negative essential thrombocythemia associated with autosomal spread of X-inactivation[J].Haematologica,2006,91:1100-1104.
8[7]VILLEVAL JL,JAMES C,PISANI DF,et al.New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients[J].Sem Thromb Haemost,2006,32:341-351.
9[8]PATEL RK,LEA NC,HENEGHAN MA,et al.Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome[J].Gastroenterology,2006,130:2031-2038.
